Omeprazole (Elderly)
Brand names: Losec, Prilosec
Omeprazole (in older people) is a proton pump inhibitor used for acid-related disorders such as reflux, peptic ulcer and gastroprotection; this page focuses on PPI use in the elderly.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
It irreversibly inhibits the gastric H+/K+-ATPase (proton pump) in parietal cells, profoundly reducing gastric acid secretion.
Prescribing in practice
- In older people review the ongoing need and deprescribe when possible, as long-term PPI use is associated with hypomagnesaemia, increased fracture risk, vitamin B12 deficiency, Clostridioides difficile and other enteric infections, and hyponatraemia.
- It inhibits CYP enzymes and reduces the antiplatelet effect of clopidogrel; review interacting medicines.
- PPIs can mask the symptoms of gastric cancer, so investigate alarm features before attributing them to benign reflux.
Monitoring
On prolonged therapy in older patients consider checking magnesium and, where relevant, vitamin B12, and periodically reassess whether continued treatment is needed.
Counselling the patient
- Take before food, typically before breakfast, for best effect.
- Tell a clinician about muscle cramps, tingling or persistent diarrhoea on long-term use.
Evidence & guidelines
MHRA advice notes the risk of hypomagnesaemia and fractures with prolonged PPI use, supporting periodic review and deprescribing in older adults.
Reference: NICE NG1; SIGN 142; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- SCORE2-OP — 5/10-Year CVD Risk (Age ≥ 70) · Cardiovascular Risk
- SMART Risk Score for Recurrent CVD · Cardiovascular Risk
- IABP Timing Assessment · Mechanical Circulatory Support
- PCSK9 Inhibitor Eligibility Assessment · Lipid Management
- Hearing Handicap Inventory for the Elderly — Screening (HHIE-S) · Hearing
- Clinical Frailty Scale (CFS) · Prognosis
- Falls Assessment in Older Adults · NICE CG161 2013
- Delirium Outside ICU · NICE CG103
- Comprehensive Geriatric Assessment (CGA) · BGS / NICE
- Delirium Assessment and Management · NICE CG103 2010
- Frailty Recognition and Management · BGS Frailty Framework / NHS NHSE
- Polypharmacy and Medicines Optimisation · STOPP/START v2 2014 / NICE NG5